Werewolf Therapeutics, Inc. (HOWL)
0.9796
+0.07
(+7.65%)
USD |
NASDAQ |
Oct 09, 16:00
0.9792
0.00 (0.00%)
After-Hours: 20:00
Werewolf Therapeutics Enterprise Value : 25.62M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 25.62M |
| October 08, 2026 | 22.24M |
| October 07, 2026 | 22.73M |
| October 06, 2026 | 22.73M |
| October 05, 2026 | 23.21M |
| October 02, 2026 | 23.12M |
| October 01, 2026 | 20.85M |
| September 30, 2026 | 22.84M |
| September 29, 2026 | 22.24M |
| September 28, 2026 | 23.21M |
| September 25, 2026 | 24.66M |
| September 24, 2026 | 25.69M |
| September 23, 2026 | 26.10M |
| September 22, 2026 | 25.74M |
| September 21, 2026 | 25.64M |
| September 18, 2026 | 24.91M |
| September 17, 2026 | 24.81M |
| September 16, 2026 | 22.68M |
| September 15, 2026 | 25.64M |
| September 14, 2026 | 24.57M |
| September 11, 2026 | 25.74M |
| September 10, 2026 | 26.05M |
| September 09, 2026 | 24.91M |
| September 08, 2026 | 25.64M |
| September 04, 2026 | 24.97M |
| Date | Value |
|---|---|
| September 03, 2026 | 23.88M |
| September 02, 2026 | 26.53M |
| September 01, 2026 | 24.55M |
| August 31, 2026 | 23.74M |
| August 28, 2026 | 23.86M |
| August 27, 2026 | 25.19M |
| August 26, 2026 | 26.07M |
| August 25, 2026 | 21.27M |
| August 24, 2026 | 20.94M |
| August 21, 2026 | 20.46M |
| August 20, 2026 | -1.031M |
| August 19, 2026 | -2.095M |
| August 18, 2026 | -2.100M |
| August 17, 2026 | -2.280M |
| August 14, 2026 | -2.319M |
| August 13, 2026 | -3.228M |
| August 12, 2026 | -3.427M |
| August 11, 2026 | -3.340M |
| August 10, 2026 | -3.422M |
| August 07, 2026 | -2.688M |
| August 06, 2026 | -2.411M |
| August 05, 2026 | -2.450M |
| August 04, 2026 | -1.838M |
| August 03, 2026 | -4.122M |
| July 31, 2026 | -4.827M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.631B |
| Oncolytics Biotech, Inc. | 65.76M |
| Sangamo Therapeutics, Inc. | 52.97M |
| Sarepta Therapeutics, Inc. | 2.143B |
| Anixa Biosciences, Inc. | 85.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.67M |
| Revenue (Quarterly) | 21.00M |
| Total Expenses (Quarterly) | 17.33M |
| EPS Diluted (Quarterly) | 0.0755 |
| Gross Profit Margin (Quarterly) | 88.32% |
| Profit Margin (Quarterly) | 17.48% |
| Earnings Yield | -75.40% |
| Normalized Earnings Yield | -66.01 |